Doc.ai describes itself as “a conversational platform for on-demand, quantified biology.”
Find out what that means today in our Doc.ai review.
What Is Doc.ai?
Doc.ai is a San Francisco-based digital health startup that just announced the launch of its blockchain-based natural language processing (NLP) platform. The platform is catered towards the quantified biology world.
Doc.ai was founded by entrepreneur Walter De Brouwer in 2016. The goal of the company is to use blockchain technology to timestamp datasets and decentralize artificial intelligence, helping to generate insights from combined medical data.
In more straightforward terms, Doc.ai is a blockchain-based platform that would allow patients to have human-like conversations with a robot doctor. Medical companies can use the Doc.ai platform to give patients access to AI-powered conversations about their health at any time of day.
Doc.ai is planning to introduce three AI-powered natural language processing modules to medical providers and payers over the next year.
The Doc.ai NLP platform for quantified biology will involve at least three core components. Doc.ai is planning to roll out these components over the next 12 months.
Designed to improve the comprehension of genetic data while providing users with decision support. This agent supports upsells, test result comprehension, genetics education, genetic counseling preparation, and in-app appointments.
This agent will answer any question about 400+ blood biomarkers. These biomarkers are based on the patient’s age, gender, and medical history. The robot will answer these questions with detailed content – including images and videos explaining the importance and relevance of these biomarkers.
This agent is a patent-pending Selfie2BMI module that uses Deep Neural Network and optimization techniques to predict a variety of anatomic features about a patient, including their height, weight, and gender, just from looking at the patient’s face.
Doc.ai has already introduced at least one of these agents to the market for testing. In July 2017, Doc.ai partnered with Dallas’s Deloitte Life Sciences and Healthcare to test its Robo-Hematology solution.
Doc.ai also has an onboarding platform that will verify and load patients in preparation for being added to a healthcare company’s database.
How Does Doc.ai Work?
Doc.ai is an artificial intelligence technology that uses a decentralized, edge-learning network to build insights based on a patient’s personal data. These types of networks are called “edge-learning” because they perform deep learning computations at the edge of the network or on a mobile device.
Doc.ai also personalizes conversations with patients on their health data via a mobile app. The platform can also provide information 24 hours a day, 7 days a week. A patient can ask the AI questions like, “What should the levels of iron in my blood be based on my iron storage deficiency”, for example, or “How do I decrease my cholesterol within the next 3 weeks.”
The AI provides an answer to these questions while also giving the context. Patients can use these conversations to achieve better health outcomes from consultations with their physician.
The end result is that lab tests can converse directly with patients through the use of artificial intelligence. Patients can effectively ask the lab test a question. They can look at the data collected during the lab test, then ask questions to determine what that information means and why it may be relevant.
The Doc.ai Token Sale
Doc.ai will create digital tokens called Neurons (NRNs) to power the platform and incentivize the community. The tokens are ERC20-complient Ethereum tokens.
The pre-sale begins on September 7, with a general crowdsale excepted to begin on September 28.
The total supply of NRNs is based on a specific number: the total supply will equal the number of neurons in the human brain, which is about 86 billion. A total of 860 million NRN will be created, with each NRN representing 100 neurons in the human brain.
Approximately 37% of NRNs are expected to be sold in the crowdsale. Investors will receive Simple Agreements for Future Tokens (SAFTs) instead of the actual tokens themselves.
Funds raised during the token sale will be used to further development the Doc.ai platform and technology.
Doc.ai is headquartered in Palo Alto, California. The company was founded by Cheryl Greene, Anthea Chung, Sam De Brouwer, and Walter De Brouwer on August 4, 2016.
So far, Doc.ai has raised an undisclosed amount of funding from Comet Labs, F50, Legend Star, and S2 Capital.
Doc.ai is a SaaS company that’s introducing blockchain technology to the medical community. The Palo Alto-based company is introducing three blockchain-based solutions over the next 12 months. These solutions involve medical robots that can communicate with patients using natural language. It’s the first step towards creating robot doctors. The various Doc.ai products help patients gain further insights into their medical status and the context of their lab results.
The Doc.ai crowdsale is taking place throughout September and October. Stay tuned for more information about the company by visiting Doc.ai.